CA2469435A1 - Modulators of lxr - Google Patents
Modulators of lxr Download PDFInfo
- Publication number
- CA2469435A1 CA2469435A1 CA002469435A CA2469435A CA2469435A1 CA 2469435 A1 CA2469435 A1 CA 2469435A1 CA 002469435 A CA002469435 A CA 002469435A CA 2469435 A CA2469435 A CA 2469435A CA 2469435 A1 CA2469435 A1 CA 2469435A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- aryl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34270701P | 2001-12-21 | 2001-12-21 | |
US60/342,707 | 2001-12-21 | ||
PCT/US2002/041306 WO2003059884A1 (en) | 2001-12-21 | 2002-12-20 | Modulators of lxr |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2469435A1 true CA2469435A1 (en) | 2003-07-24 |
Family
ID=23342938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002469435A Abandoned CA2469435A1 (en) | 2001-12-21 | 2002-12-20 | Modulators of lxr |
Country Status (7)
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002351412B2 (en) | 2001-12-21 | 2010-05-20 | Exelixis Patent Company Llc | Modulators of LXR |
EP1465882B1 (en) | 2001-12-21 | 2011-08-24 | X-Ceptor Therapeutics, Inc. | Hetrocyclic modulators of nuclear receptors |
US7482366B2 (en) * | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
EP1511483A4 (en) * | 2002-03-27 | 2009-03-18 | Smithkline Beecham Corp | PROCESSING METHODS USING LXR MODULATORS |
DE602004022819D1 (de) | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
CA2534567A1 (en) * | 2003-08-18 | 2005-03-03 | Wyeth | Novel human lxr alpha variants |
NZ547696A (en) | 2003-12-23 | 2009-12-24 | Astex Therapeutics Ltd | Pyrazole derivatives as protein kinase modulators |
WO2005100396A1 (en) * | 2004-04-16 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with retinoid x receptor alpha (rxra) |
GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
EP1806332A4 (en) | 2004-10-27 | 2010-03-31 | Daiichi Sankyo Co Ltd | BENZENE COMPOUND HAVING TWO OR MORE TWO SUBSTITUENTS |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
AU2005310467B2 (en) * | 2004-12-01 | 2011-06-23 | Msd K.K. | Substituted pyridone derivative |
WO2006077012A2 (en) * | 2005-01-18 | 2006-07-27 | Genfit S.A. | USE OF LXR LIGANDS FOR THE MODULATION OF DENDRITIC CELLS (DCs) |
JP2008546751A (ja) | 2005-06-22 | 2008-12-25 | アステックス・セラピューティクス・リミテッド | 医薬組成物 |
EP1933832A2 (en) | 2005-06-23 | 2008-06-25 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
US7790745B2 (en) * | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
US7741317B2 (en) * | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
NZ571182A (en) | 2006-04-04 | 2010-09-30 | Univ California | Pyrazolo[3,4-d]pyrimidines |
FR2903105A1 (fr) | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique |
FR2903107B1 (fr) | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
WO2008036238A2 (en) * | 2006-09-19 | 2008-03-27 | Wyeth | Use of lxr modulators for the prevention and treatment of skin aging |
US20090012053A1 (en) * | 2006-09-19 | 2009-01-08 | Wyeth | Use of LXR agonists for the treatment of osteoarthritis |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
ES2388967T3 (es) * | 2007-05-04 | 2012-10-22 | Bristol-Myers Squibb Company | Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G |
ES2388315T3 (es) | 2007-05-04 | 2012-10-11 | Bristol-Myers Squibb Company | Agonistas [6,5]-bicíclicos de receptores GPR119 acoplados a la proteína G |
JPWO2008149965A1 (ja) | 2007-06-07 | 2010-08-26 | アステラス製薬株式会社 | ピリドン化合物 |
ATE540945T1 (de) * | 2007-07-17 | 2012-01-15 | Bristol Myers Squibb Co | Verfahren zur modulation des gpr119-g- proteingekoppelten rezeptors und ausgewählte verbindungen |
AR068813A1 (es) * | 2007-08-30 | 2009-12-09 | Takeda Pharmaceutical | Derivados de pirazol sustituidos como antagonistas del receptor de androgenos (ar), un agente farmaceutico que los comprende y su uso en el tratamiento del cancer de prostata |
KR101533440B1 (ko) | 2007-09-14 | 2015-07-03 | 얀센 파마슈티칼스 인코포레이티드 | 1´,3´-이치환된-4-페닐-3,4,5,6-테트라히드로-2h,1´h-[1,4´]비피리디닐-2´-온 |
BRPI0817101A2 (pt) | 2007-09-14 | 2017-05-09 | Addex Pharmaceuticals Sa | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas |
GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
SG187425A1 (en) | 2008-01-04 | 2013-02-28 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US20090209601A1 (en) * | 2008-02-15 | 2009-08-20 | Wyeth | Use of rxr agonists for the treatment of osteoarthritis |
BRPI0908417B1 (pt) | 2008-02-26 | 2022-01-11 | Takeda Pharmaceutical Company Limited | Composto, e, uso do composto |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン, エルエルシー | キナーゼ阻害剤および使用方法 |
JPWO2009154190A1 (ja) | 2008-06-17 | 2011-12-01 | アステラス製薬株式会社 | ピリドン化合物 |
WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
CA2730106A1 (en) | 2008-07-08 | 2010-01-14 | Intellikine, Inc. | Kinase inhibitors and methods of use |
TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
ES2439291T3 (es) | 2008-09-02 | 2014-01-22 | Janssen Pharmaceuticals, Inc. | Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos |
WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
PL3135672T3 (pl) * | 2008-10-10 | 2020-11-16 | Vm Discovery, Inc. | Kompozycje i sposoby leczenia zaburzeń używania alkoholu, bólu i innych chorób |
EP2358720B1 (en) | 2008-10-16 | 2016-03-02 | The Regents of The University of California | Fused ring heteroaryl kinase inhibitors |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
US8691813B2 (en) | 2008-11-28 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
MY161325A (en) | 2009-05-12 | 2017-04-14 | Janssen Pharmaceuticals Inc | 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
EA020671B1 (ru) | 2009-05-12 | 2014-12-30 | Янссен Фармасьютикалз, Инк. | ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 |
US8486965B2 (en) | 2009-08-26 | 2013-07-16 | Takeda Pharmaceutical Company Limited | Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer |
KR20120078703A (ko) | 2009-08-26 | 2012-07-10 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합 헤테로시클릭 고리 유도체 및 이의 용도 |
US8927718B2 (en) | 2009-08-26 | 2015-01-06 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
JP5659159B2 (ja) | 2009-08-26 | 2015-01-28 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
JP2013523822A (ja) | 2010-04-08 | 2013-06-17 | ブリストル−マイヤーズ スクイブ カンパニー | Gpr119修飾因子としてのピリミジニルピペリジニルオキシピリジノ類似体 |
US8729084B2 (en) | 2010-05-06 | 2014-05-20 | Bristol-Myers Squibb Company | Benzofuranyl analogues as GPR119 modulators |
CN103002738A (zh) | 2010-05-21 | 2013-03-27 | 英特利凯恩有限责任公司 | 用于激酶调节的化学化合物、组合物和方法 |
JP2013542183A (ja) | 2010-09-07 | 2013-11-21 | エスエヌユー アールアンドディービー ファウンデーション | セスタテルペン化合物およびこれらの物質の用途 |
PT2649069E (pt) | 2010-11-08 | 2015-11-20 | Janssen Pharmaceuticals Inc | Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2 |
JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PE20141303A1 (es) | 2011-01-10 | 2014-10-01 | Infinity Pharmaceuticals Inc | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas |
CA2828483A1 (en) | 2011-02-23 | 2012-11-01 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
WO2012158784A2 (en) * | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
JP6027610B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
US8785470B2 (en) | 2011-08-29 | 2014-07-22 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2846496C (en) | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
JP2015532287A (ja) | 2012-09-26 | 2015-11-09 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ire1の調節 |
US9006242B2 (en) | 2012-10-15 | 2015-04-14 | Epizyme, Inc. | Substituted benzene compounds |
JP6456909B2 (ja) | 2013-03-15 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Lxr調節因子 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
EP2968275B1 (en) | 2013-03-15 | 2017-11-29 | Bristol-Myers Squibb Company | Lxr modulators |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
MA38661A1 (fr) | 2013-06-27 | 2017-03-31 | Pfizer | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
PE20160685A1 (es) | 2013-10-04 | 2016-07-23 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
IL279202B2 (en) | 2014-01-21 | 2023-09-01 | Janssen Pharmaceutica Nv | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use |
KR20220039824A (ko) | 2014-01-21 | 2022-03-29 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
JP6701088B2 (ja) | 2014-03-19 | 2020-05-27 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | Pi3k−ガンマ媒介障害の治療で使用するための複素環式化合物 |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
US10583102B2 (en) | 2014-10-06 | 2020-03-10 | The Johns Hopkins University | Targeting liver nuclear receptors as a treatment for wilson disease |
CA2998469A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
JP7025022B2 (ja) | 2016-01-11 | 2022-02-24 | ザ ロックフェラー ユニバーシティー | 骨髄系由来抑制細胞関連障害の治療のための方法 |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2018016227A (es) | 2016-06-24 | 2019-07-08 | Infinity Pharmaceuticals Inc | Terapias de combinacion. |
WO2018017910A1 (en) | 2016-07-22 | 2018-01-25 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
US20230132366A9 (en) | 2018-11-26 | 2023-04-27 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
AU2020401286A1 (en) | 2019-12-13 | 2022-06-23 | Inspirna, Inc. | Metal salts and uses thereof |
Family Cites Families (243)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US72073A (en) | 1867-12-10 | Improved boot and shoe-heels | ||
US54759A (en) * | 1866-05-15 | Improvement in pantographic machines | ||
US160818A (en) * | 1875-03-16 | Improvement in bucket-ears | ||
US176064A (en) * | 1876-04-11 | Improvement in screw-cutting machines | ||
US624583A (en) * | 1899-05-09 | Paper box | ||
US226727A (en) * | 1880-04-20 | Car-coupling | ||
US137805A (en) * | 1873-04-15 | Improvement in broom-corn dusters | ||
US51813A (en) * | 1866-01-02 | Improvement in the manufacture of paper-pulp | ||
US73277A (en) * | 1868-01-14 | Improvement in gates | ||
US294995A (en) * | 1884-03-11 | Ments | ||
US2556A (en) * | 1842-04-16 | Stove | ||
US339105A (en) * | 1886-03-30 | John l | ||
US236581A (en) * | 1881-01-11 | haworth | ||
US147493A (en) * | 1874-02-17 | Improvement in curtain-cord holders | ||
US17334A (en) * | 1857-05-19 | Machinery for dressing sewing-thread | ||
US557843A (en) * | 1896-04-07 | Octave-coupler for organs | ||
US103705A (en) * | 1870-05-31 | Improvement in scissors-sharpener | ||
US122964A (en) * | 1872-01-23 | 1872-01-23 | Improvement in watches | |
US755934A (en) * | 1904-02-17 | 1904-03-29 | George M Potter | Detonator. |
US1226832A (en) * | 1916-08-09 | 1917-05-22 | Fred M Webber | Pneumatic pitman-balance for swing-jaw rock and ore crushers. |
US1261371A (en) * | 1917-05-02 | 1918-04-02 | John Ellingsen | Window construction. |
US5625041A (en) | 1990-09-12 | 1997-04-29 | Delta Biotechnology Limited | Purification of proteins |
US2077412A (en) * | 1930-06-04 | 1937-04-20 | Eugene J Lorand | Process for the preparation of a molded cellulose foam from viscose and product thereof |
US2345058A (en) * | 1939-11-25 | 1944-03-28 | Aetna Standard Eng Co | Method of galvanizing |
US2824341A (en) * | 1953-11-25 | 1958-02-25 | Harold B Neal | Awning |
DE1189994B (de) * | 1957-11-20 | 1965-04-01 | Hoechst Ag | Verfahren zur Herstellung von 1-Aminopyridon-(6)-derivaten |
CH477475A (de) * | 1966-07-25 | 1969-08-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen Derivaten der 6-Amino-penicillansäure |
US3576814A (en) * | 1970-01-30 | 1971-04-27 | Rohm & Haas | N-aryl pyrid-2-ones |
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
US4159202A (en) | 1973-12-20 | 1979-06-26 | Hoechst Aktiengesellschaft | Photopolymer having 2-pyridone side group |
US3954734A (en) | 1974-01-21 | 1976-05-04 | Parke, Davis & Company | Novel antibacterial amide compounds and process means for producing the same |
US4028084A (en) * | 1974-10-11 | 1977-06-07 | Rohm And Haas Company | Derivatives of 3-carboxy pyrid-2-ones |
US4038065A (en) | 1974-10-11 | 1977-07-26 | Rohm And Haas Company | 1-alkylpyrid-2-one |
US3951982A (en) | 1974-11-21 | 1976-04-20 | Parke, Davis & Company | Trialkylsilyl esters of 6(substituted amino)phenyl-1,-dihydro-2-oxonicotinic acid, methods for their production and conversion to the corresponding acid chlorides |
US4053470A (en) | 1974-12-23 | 1977-10-11 | Parke, Davis & Company | Substituted-1,2-dihydro-2-oxonicotinyl-cephalosporins |
IT1039699B (it) | 1975-07-03 | 1979-12-10 | Prephar | Composizione spermicida a base di derivati benzisotiazolici |
DE2637477A1 (de) | 1976-08-20 | 1978-02-23 | Hoechst Ag | Dihydro-oxo-nicotinsaeuren und verfahren zu ihrer herstellung |
JPS5350179A (en) * | 1976-10-15 | 1978-05-08 | Rikagaku Kenkyusho | Novel 2-pyridone compounds and their preparation |
US4101661A (en) | 1977-06-03 | 1978-07-18 | Warner-Lambert | Novel antibacterial amide compounds and process means for producing the same |
CA1115278A (en) | 1979-01-10 | 1981-12-29 | Benjamin J. Pierce | Anti-inflammatory 4-pyridones and their preparation |
GB2045236A (en) | 1979-03-26 | 1980-10-29 | Hoechst Uk Ltd | Oxapenem derivatives |
FR2456713A1 (fr) * | 1979-05-17 | 1980-12-12 | Emballage Ste Gle Pour | Melanges vitrifiables |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
JPS5726653A (en) | 1980-05-09 | 1982-02-12 | Ciba Geigy Ag | Substituted phenyl ether |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US4309552A (en) * | 1980-08-07 | 1982-01-05 | A. H. Robins Company, Inc. | Synthesis of 4-nitro-1,2-hydrocarbyl pyrazolidines and process for preparation thereof |
EP0051813B1 (en) | 1980-11-06 | 1986-07-30 | Hoechst Uk Limited | 7-oxo-4-thia-1-aza(3,2,0)heptane and 7-oxo-4-thia-1-aza(3,2,0)hept-2-ene derivatives |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
FI844067L (fi) | 1983-10-19 | 1985-04-20 | Lilly Co Eli | Foerfarande foer framstaellning av 9-karbamoylfluorenderivat. |
US4585894A (en) | 1983-10-19 | 1986-04-29 | Eli Lilly And Company | Process for producing 9-carbamoyl fluorene derivatives |
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
DD244341A1 (de) | 1985-12-18 | 1987-04-01 | Akad Wissenschaften Ddr | Verfahren zur herstellung neuer 1h-pyrid-2-one |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5221623A (en) | 1986-07-22 | 1993-06-22 | Boyce Thompson Institute For Plant Research, Inc. | Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms |
US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
JPS63112566A (ja) | 1986-10-28 | 1988-05-17 | Nissan Chem Ind Ltd | ピリミジノン誘導体、その製法および殺虫・殺ダニ・殺菌剤 |
US4968707A (en) | 1987-06-10 | 1990-11-06 | Pfizer Inc. | Oxazolidin-2-one derivatives as hypoglycemic agents |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5070012A (en) | 1988-03-30 | 1991-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Monitoring of cells and trans-activating transcription elements |
US5194438A (en) | 1988-07-15 | 1993-03-16 | Basf Aktiengesellschaft | α-arylacrylates substituted by a trifluoromethylpyrimidinyloxy radical, fungicidal compositions and methods |
DE3823991A1 (de) | 1988-07-15 | 1990-02-15 | Basf Ag | Heterocyclisch substituierte (alpha)-aryl-acrylsaeureester und fungizide, die diese verbindungen enthalten |
DE3922392A1 (de) | 1989-07-07 | 1991-01-17 | Merck Patent Gmbh | Chromanderivate |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
DE3934176A1 (de) | 1989-10-13 | 1991-04-18 | Basf Ag | Cyclische amide |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
KR100196559B1 (ko) | 1990-06-19 | 1999-06-15 | 기따사또 이찌로 | 안지오텐신ii 길항작용을 함유하는 피리딘 유도체 |
US5283179A (en) | 1990-09-10 | 1994-02-01 | Promega Corporation | Luciferase assay method |
US5380721A (en) | 1990-09-10 | 1995-01-10 | Sterling Winthrop Inc. | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents |
AU8940491A (en) | 1990-10-31 | 1992-05-26 | Smithkline Beecham Corporation | Substituted indolizino(1,2-b)quinolinones |
WO1993020818A1 (en) | 1990-10-31 | 1993-10-28 | Smithkline Beecham Corporation | SUBSTITUTED INDOLIZINO[1,2-b]QUINOLINONES |
US5883255A (en) | 1990-10-31 | 1999-03-16 | Smithkline Beecham Corporation | Substituted indolizino 1,2-b!quinolinones |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
IL100917A0 (en) * | 1991-02-16 | 1992-11-15 | Fisons Plc | Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them |
DE4129340A1 (de) | 1991-09-04 | 1993-03-11 | Merck Patent Gmbh | 1,2-dihydro-2-oxopyridine |
US5332750A (en) | 1991-09-04 | 1994-07-26 | Merck Patent Gesellschaft Mit Beschrankter Haftung | 1,2-dihydro-2-oxopyridines |
ATE215601T1 (de) | 1991-09-17 | 2002-04-15 | Salk Inst For Biological Studi | Rezeptoren der steroid/thyroid superfamilie von rezeptoren |
DE4221583A1 (de) * | 1991-11-12 | 1993-05-13 | Bayer Ag | Substituierte biphenylpyridone |
US5278289A (en) | 1991-11-12 | 1994-01-11 | Johnson Alan J | Antihemophilic factor stabilization |
US5504070A (en) | 1991-12-05 | 1996-04-02 | Berlex Laboratories, Inc. | Inhibitors of the conversion of big endothelin to endothelin |
EP0551572B1 (en) | 1991-12-10 | 1998-12-30 | Bristol-Myers Squibb Company | Tibial resector guide |
DE4141187A1 (de) | 1991-12-13 | 1993-06-17 | Bayer Ag | Verfahren zur herstellung von substituierten pyrazolinen |
AU668694B2 (en) | 1991-12-19 | 1996-05-16 | Sanofi-Synthelabo | Saccharin derivative proteolytic enzyme inhibitors |
US5378720A (en) | 1991-12-19 | 1995-01-03 | Sterling Winthrop Inc. | Saccharin derivative proteolytic enzyme inhibitors |
ES2113399T3 (es) | 1991-12-26 | 1998-05-01 | Mitsubishi Chem Corp | Derivados de beta-oxo-beta-bencenopropano-tio-amida. |
WO1993016698A1 (en) | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | SUBSTITUTED FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES |
DE4206045A1 (de) | 1992-02-27 | 1993-09-02 | Bayer Ag | Sulfonylbenzyl substituierte pyridone |
EP0649306B1 (en) | 1992-05-20 | 2001-01-10 | Merck & Co. Inc. | Ester derivatives of 4-aza-steroids |
ATE195530T1 (de) | 1992-05-20 | 2000-09-15 | Merck & Co Inc | 17-ether und thioether von 4-aza-steroiden |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
GB9213694D0 (en) | 1992-06-27 | 1992-08-12 | Keynes Roger J | Improvements in or relating to neuroregeneration |
US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
GB9221329D0 (en) | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
DE4319040A1 (de) | 1992-10-23 | 1994-04-28 | Bayer Ag | Alkoxymethylsubstituierte Pyridonbiphenyle |
DE4319041A1 (de) * | 1992-10-23 | 1994-04-28 | Bayer Ag | Trisubstituierte Biphenyle |
DE4309552A1 (de) | 1993-03-24 | 1994-09-29 | Bayer Ag | Substituierte Stickstoff-Heterocyclen |
US5814645A (en) | 1993-03-24 | 1998-09-29 | Bayer Aktiengesellschaft | Arylor hetaryl substituted nitrogen heterocycles and their use as pesticides |
DE4313747A1 (de) | 1993-04-27 | 1994-11-03 | Bayer Ag | Verfahren zur Herstellung von substituierten Biphenyltetrazolen |
DE4316077A1 (de) * | 1993-05-13 | 1994-11-17 | Bayer Ag | Substituierte Mono- und Bihydridylmethylpyridone |
AP9400651A0 (en) | 1993-07-15 | 1995-12-30 | Pfizer | Azacyclic-heterocyclic compounds as angiotensin II receptor antagonists. |
WO1995003803A1 (en) | 1993-08-03 | 1995-02-09 | Smithkline Beecham Corporation | SUBSTITUTED FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES |
US5514716A (en) | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
DE4407488A1 (de) | 1994-03-07 | 1995-09-14 | Bayer Ag | Verwendung von Biphenyl- und Pyridylmethylpyridonen |
US5684022A (en) | 1994-04-08 | 1997-11-04 | Sumitomo Chemical Company, Limited | Ether compounds, their use, and intermediates for use in their production |
US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
DE4414648A1 (de) | 1994-04-27 | 1995-11-02 | Merck Patent Gmbh | Verfahren zur Umsetzung von substituierten Pyrid-2-onen mit Arylalkylhalogeniden |
US5598269A (en) | 1994-05-12 | 1997-01-28 | Children's Hospital Medical Center | Laser guided alignment apparatus for medical procedures |
WO1996003378A1 (fr) | 1994-07-26 | 1996-02-08 | Sankyo Company, Limited | Derives d'amide n-phenyle et d'uree |
JP3466765B2 (ja) | 1994-07-27 | 2003-11-17 | キッコーマン株式会社 | ビオチン化ホタルルシフェラーゼ、ビオチン化ホタルルシフェラーゼ遺伝子、新規な組み換え体dna、ビオチン化ホタルルシフェラーゼの製造法及び生物発光分析法 |
US5698571A (en) | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
US5744482A (en) | 1994-10-05 | 1998-04-28 | Eli Lilly And Company | Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine |
WO1996012181A1 (en) | 1994-10-12 | 1996-04-25 | Research & Diagnostics Systems, Inc. | Reticulocyte assay control |
US5659042A (en) | 1994-10-25 | 1997-08-19 | Allergan | Method for preparing esters of halonicotinic acids |
US5607967A (en) | 1994-10-27 | 1997-03-04 | Merck & Co., Inc. | Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
US5955108A (en) | 1994-12-16 | 1999-09-21 | Quadrant Healthcare (Uk) Limited | Cross-linked microparticles and their use as therapeutic vehicles |
US5618943A (en) | 1994-12-29 | 1997-04-08 | Allergan | Acetylenes disubstituted with a 5 OXO substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
US5618931A (en) | 1994-12-29 | 1997-04-08 | Allergan | Acetylenes disubstituted with a 5 substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
US5599967A (en) | 1994-12-29 | 1997-02-04 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity |
US5648514A (en) | 1994-12-29 | 1997-07-15 | Allergan | Substituted acetylenes having retinoid-like biological activity |
US5543534A (en) | 1994-12-29 | 1996-08-06 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity |
AU698527B2 (en) | 1994-12-29 | 1998-10-29 | Allergan, Inc. | Acetylenes disubstituted with a 5 or 8 substituted tetrahydronaphthyl or dihydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity |
US5514825A (en) | 1994-12-29 | 1996-05-07 | Allergan, Inc. | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
US6005086A (en) | 1995-01-13 | 1999-12-21 | The Salk Institute For Biological Studies | Farnesoid activated receptor polypeptides, and nucleic acid encoding the same |
US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
US5869428A (en) | 1995-03-13 | 1999-02-09 | Ishihara Sangyo Kaisha Ltd. | Pyridonesulfonylurea compounds, process for their production and herbicides containing them |
US5741657A (en) | 1995-03-20 | 1998-04-21 | The Regents Of The University Of California | Fluorogenic substrates for β-lactamase and methods of use |
DE19518739A1 (de) | 1995-05-22 | 1996-11-28 | Basf Ag | N-Aminopyridonderivate |
JPH08325248A (ja) | 1995-05-26 | 1996-12-10 | Chugoku Kayaku Kk | テトラゾール類の新規な合成試薬及びそれを用いたテトラゾール類の製造方法 |
US5612363A (en) | 1995-06-02 | 1997-03-18 | Berlex Laboratories, Inc. | N,N-di(aryl) cyclic urea derivatives as anti-coagulants |
DK0831910T3 (da) | 1995-06-07 | 2002-05-21 | Searle & Co | Kombinationsterapi med epoxy-steroid aldosteronantagonist og angiotensin II-receptorantagonist til behandling af kongestivt hjertesvigt |
JPH11509838A (ja) | 1995-06-07 | 1999-08-31 | ジー.ディー.サール アンド カンパニー | 充血性心不全症を処置するためのスピロノラクトン化合物とアンギオテンシンii拮抗物質との組合わせ治療 |
AU5982296A (en) | 1995-06-07 | 1996-12-30 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination of an angi otensin ii antagonist and spironolactone |
WO1996041633A1 (en) | 1995-06-08 | 1996-12-27 | Eli Lilly And Company | Methods of treating cold and allergic rhinitis |
AU5966096A (en) | 1995-06-09 | 1997-01-09 | Eli Lilly And Company | Methods of treating cold and allergic rhinitis |
US5849587A (en) | 1995-06-09 | 1998-12-15 | Cornell Research Foundation, Inc. | Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells |
DE19527568A1 (de) | 1995-07-28 | 1997-01-30 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
US6008204A (en) | 1995-09-01 | 1999-12-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5952345A (en) | 1995-09-01 | 1999-09-14 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5958954A (en) | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5776699A (en) | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
KR19990063632A (ko) | 1995-09-21 | 1999-07-26 | 디 헤이쓰, 산드라 우드 | 약물 운송용 트란스사이토시스 매개체 및 상승제 |
US5888830A (en) | 1995-09-22 | 1999-03-30 | Berlex Laboratories, Inc. | Apparatus and process for multiple chemical reactions |
IL123662A (en) | 1995-09-22 | 2001-01-28 | Berlex Lab | Apparatus and process for multiple chemical reactions |
CA2236007A1 (en) | 1995-10-31 | 1997-07-17 | Gerald Floyd Smith | Antithrombotic diamines |
US5994375A (en) | 1996-02-12 | 1999-11-30 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants |
WO1997031947A1 (en) | 1996-02-29 | 1997-09-04 | Delta Biotechnology Limited | High purity albumin production process |
US5877207A (en) | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
CN1218368A (zh) | 1996-03-15 | 1999-06-02 | 伊莱利利公司 | 治疗感冒或过敏性鼻炎的方法 |
US5869497A (en) | 1996-03-15 | 1999-02-09 | Eli Lilly And Company | Method of treating or ameliorating the symptoms of common cold or allergic rhinitis |
DE19619950A1 (de) | 1996-04-17 | 1997-10-23 | Bayer Ag | Heterocyclisch-substituierte Phenylglycinolamide |
EP0802192A1 (de) | 1996-04-17 | 1997-10-22 | Bayer Ag | Heterocyclisch-substituierte Phenylglycinolamide mit antiatherosklerotischer Wirkung und Verfahren zu ihrer Herstellung |
US5723666A (en) | 1996-06-21 | 1998-03-03 | Allergan | Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5808124A (en) | 1996-06-21 | 1998-09-15 | Allergan | O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US6555690B2 (en) | 1996-06-21 | 2003-04-29 | Allergan, Inc. | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5747542A (en) | 1996-06-21 | 1998-05-05 | Allergan | Oxo-substituted tetrahydronaphthalene derivatives having retinold and/or retinoid antagonist-like biological activity |
ATE265997T1 (de) | 1996-06-21 | 2004-05-15 | Allergan Inc | Substituierte tetrahydronaphthalin- und dihydronaphthalin-derivate mit einer retinoiden und/oder retinoid antagonist-ähnlichen biologischen aktivität |
US5773594A (en) | 1996-06-21 | 1998-06-30 | Allergan | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5763635A (en) | 1996-06-21 | 1998-06-09 | Allergan | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity |
US5741896A (en) | 1996-06-21 | 1998-04-21 | Allergan | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5618503A (en) | 1996-06-28 | 1997-04-08 | Chemical Research & Licensing Company | Antimony pentafluoride |
DE19627421A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Verwendung von substituierten Biphenylen |
US5962473A (en) | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
US5693641A (en) | 1996-08-16 | 1997-12-02 | Berlex Laboratories Inc. | Bicyclic pyrimidine derivatives and their use as anti-coagulants |
US5753635A (en) | 1996-08-16 | 1998-05-19 | Berlex Laboratories, Inc. | Purine derivatives and their use as anti-coagulants |
AU4074897A (en) | 1996-09-18 | 1998-04-14 | Eli Lilly And Company | A method for the prevention of migraine |
US5955604A (en) | 1996-10-15 | 1999-09-21 | The Regents Of The University Of California | Substrates for β-lactamase and uses thereof |
WO1998017115A1 (de) | 1996-10-17 | 1998-04-30 | Basf Aktiengesellschaft | Verfahren zur bekämpfung von schadpilzen in kulturpflanzen |
ZA979961B (en) | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
EP1082958A3 (en) | 1996-11-15 | 2002-12-11 | Eli Lilly And Company | 5-HT1F agonists in chronic pain |
US5728846A (en) | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
PL334840A1 (en) | 1997-01-24 | 2000-03-27 | Univ California | Application of fxr, pparalpha and lxralpha activators in order to restore the barrier function, to stimulate epithelium differentation and to inhibit proliferation |
US5855654A (en) | 1997-01-30 | 1999-01-05 | Rohm And Haas Company | Pyridazinones as marine antifouling agents |
US5760276A (en) | 1997-03-06 | 1998-06-02 | Allergan | Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity |
DE69828522T2 (de) | 1997-04-30 | 2005-12-15 | Eli Lilly And Co., Indianapolis | Antithrombotische mittel |
WO1998049161A1 (en) | 1997-04-30 | 1998-11-05 | Eli Lilly And Company | Antithrombotic agents |
JP3771672B2 (ja) | 1997-05-27 | 2006-04-26 | 曙ブレーキ工業株式会社 | ブレーキペダル操作検出装置 |
DE19729061A1 (de) | 1997-07-08 | 1999-01-14 | Agfa Gevaert Ag | Farbfotografisches Aufzeichnungsmaterial |
US6380201B1 (en) | 1997-08-05 | 2002-04-30 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F agonists |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
GB9723078D0 (en) | 1997-10-31 | 1998-01-07 | Cerebrus Ltd | Chemical compounds |
ATE388139T1 (de) | 1997-12-18 | 2008-03-15 | Boehringer Ingelheim Pharma | Pyridone als hemmer der sh2-domäne der src- familie |
US6156784A (en) | 1997-12-18 | 2000-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as phosphotyrosine mimics |
WO1999040062A1 (en) | 1998-02-05 | 1999-08-12 | Novo Nordisk A/S | Hydrazone derivatives |
AU738222B2 (en) | 1998-04-08 | 2001-09-13 | Novartis Ag | N-pyridonyl herbicides |
CA2330304A1 (en) | 1998-04-27 | 1999-11-04 | Centre National De La Recherche Scientifique | 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases |
DE19826671A1 (de) | 1998-06-16 | 1999-12-23 | Hoechst Schering Agrevo Gmbh | 1,3-Oxazolin- und 1,3-Thiazolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
EP1115853A2 (en) | 1998-09-23 | 2001-07-18 | Ludmila Solomin | Analysis of ligand activated nuclear receptors in vivo |
EP1137940A4 (en) | 1998-10-23 | 2004-06-02 | Glaxo Group Ltd | METHOD FOR IDENTIFYING LIGANDS OF NUCLEAR RECEPTORS |
EP1006108A1 (en) | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers |
EP1006112A1 (en) | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers |
GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
US6294503B1 (en) | 1998-12-03 | 2001-09-25 | Ishihara Sangyo Kaisha, Ltd. | Fused heterocycle compounds, process for their preparation, and herbicidal compositions containing them |
JP2002532729A (ja) | 1998-12-23 | 2002-10-02 | グラクソ グループ リミテッド | 核内受容体のリガンドのアッセイ |
AU2409600A (en) | 1999-01-07 | 2000-07-24 | Tularik Inc. | Fxr receptor-mediated modulation of cholesterol metabolism |
US6071955A (en) | 1999-02-25 | 2000-06-06 | The Regents Of The University Of California | FXR, PPARA and LXRA activators to treat acne/acneiform conditions |
US6316503B1 (en) | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
DE60029029T2 (de) | 1999-03-26 | 2007-06-14 | City Of Hope, Duarte | Screenen nach FXR-Rezeptormodulatoren |
AU4641400A (en) | 1999-06-02 | 2000-12-18 | Ishihara Sangyo Kaisha Ltd. | Fused tricyclic compounds, process for their preparation, and herbicidal compositions containing them |
MXPA01013174A (es) | 1999-06-18 | 2002-06-04 | Cv Therapeutics Inc | Composiciones y metodos para incrementar el flujo del colesterol y elevar hdl utilizando un cassette de enlace atp transportador de proteina abc1. |
EP1212065A4 (en) | 1999-07-08 | 2004-02-11 | Tularik Inc | COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL |
EP1239848A2 (en) | 1999-09-01 | 2002-09-18 | University of British Columbia | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
IT1317904B1 (it) | 1999-09-11 | 2003-07-15 | Glaxo Group Ltd | Formulazione farmaceutica di propionato di fluticasone. |
EP1242080A4 (en) | 1999-09-27 | 2003-01-22 | Univ Georgetown | INHIBITORS OF DOPAMINE TRANSPORT AND THEIR USE |
US6444471B1 (en) | 1999-10-18 | 2002-09-03 | Research & Diagnostic Systems, Inc. | Reticulocyte containing complete blood control |
AU1534501A (en) | 1999-11-23 | 2001-06-04 | Glaxo Group Limited | Pharmaceutical formulations of salmeterol |
CZ20022352A3 (cs) | 1999-12-06 | 2003-05-14 | F. Hoffmann-La Roche Ag | 4-pyridinyl-N-acyl-L-fenylalaniny |
US20020160067A1 (en) | 2001-04-25 | 2002-10-31 | Oncology Science Corporation | Therapeutic preparation and method for producing a therapeutic preparation using coffee beans as a substrate |
ES2238334T3 (es) | 1999-12-24 | 2005-09-01 | Glaxo Group Limited | Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona. |
AU2000235960A1 (en) | 2000-02-14 | 2001-08-27 | Tularik, Inc. | Lxr modulators |
US6378919B1 (en) | 2000-04-04 | 2002-04-30 | International Truck Intellectual Property Company, L.L.C. | Cylindrical lock with slam latch and auxiliary cable release |
JP2001302637A (ja) | 2000-04-20 | 2001-10-31 | Nippon Kayaku Co Ltd | 感熱転写記録用色素及び感熱転写シート |
WO2001082917A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
BRPI0111596B8 (pt) | 2000-06-12 | 2022-07-26 | Eisai Co Ltd | Composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto |
US6313107B1 (en) | 2000-08-29 | 2001-11-06 | Allergan Sales, Inc. | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
US6252090B1 (en) | 2000-08-29 | 2001-06-26 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6291677B1 (en) | 2000-08-29 | 2001-09-18 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6369225B1 (en) | 2000-08-29 | 2002-04-09 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6369261B1 (en) | 2000-08-29 | 2002-04-09 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6387951B1 (en) | 2000-08-29 | 2002-05-14 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6380256B1 (en) | 2000-08-29 | 2002-04-30 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6303785B1 (en) | 2000-08-29 | 2001-10-16 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
DE60116642T2 (de) | 2000-08-29 | 2006-11-09 | Allergan, Inc., Irvine | Verbindungen mit cytochrom p450ra1 hemmenden aktivität |
UY27003A1 (es) | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
NZ526622A (en) | 2000-12-11 | 2006-07-28 | Amgen Sf Llc | CXCR3 antagonists |
US8176425B2 (en) | 2001-02-02 | 2012-05-08 | Ensequence, Inc. | Animated screen object for annotation and selection of video sequences |
ATE383359T1 (de) | 2001-05-05 | 2008-01-15 | Smithkline Beecham Plc | N-aroyl zyklische amine |
AU2002341123A1 (en) | 2001-05-05 | 2002-11-18 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
WO2003002561A1 (en) | 2001-06-28 | 2003-01-09 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
AU2002351412B2 (en) | 2001-12-21 | 2010-05-20 | Exelixis Patent Company Llc | Modulators of LXR |
WO2004103974A1 (ja) | 2003-05-23 | 2004-12-02 | Japan Tobacco Inc. | 置換2-オキソキノリン化合物およびその医薬用途 |
CN1289803C (zh) | 2004-05-16 | 2006-12-13 | 王永钦 | 汽车冷却风扇驱动机构总成 |
-
2002
- 2002-12-20 AU AU2002351412A patent/AU2002351412B2/en not_active Ceased
- 2002-12-20 US US10/327,813 patent/US7998986B2/en active Active
- 2002-12-20 ES ES02787071T patent/ES2421511T3/es not_active Expired - Lifetime
- 2002-12-20 WO PCT/US2002/041306 patent/WO2003059884A1/en active Application Filing
- 2002-12-20 EP EP02787071.6A patent/EP1465869B1/en not_active Expired - Lifetime
- 2002-12-20 CA CA002469435A patent/CA2469435A1/en not_active Abandoned
- 2002-12-20 JP JP2003559988A patent/JP5082033B2/ja not_active Expired - Lifetime
-
2010
- 2010-09-22 JP JP2010212875A patent/JP2010280732A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ES2421511T3 (es) | 2013-09-03 |
WO2003059884A1 (en) | 2003-07-24 |
JP5082033B2 (ja) | 2012-11-28 |
US7998986B2 (en) | 2011-08-16 |
EP1465869A4 (en) | 2005-12-28 |
AU2002351412A1 (en) | 2003-07-30 |
US20030181420A1 (en) | 2003-09-25 |
EP1465869B1 (en) | 2013-05-15 |
EP1465869A1 (en) | 2004-10-13 |
JP2005536450A (ja) | 2005-12-02 |
AU2002351412B2 (en) | 2010-05-20 |
JP2010280732A (ja) | 2010-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2469435A1 (en) | Modulators of lxr | |
JP5017607B2 (ja) | 核レセプターのモジュレーター | |
JP5237799B2 (ja) | ピラゾールベースのlxrモジュレーター | |
EP0733033B1 (en) | Pharmaceutically active substituted aromatic compounds | |
JP5260569B2 (ja) | 置換ピラゾール、このような化合物を含有する組成物及び使用方法 | |
US11447453B2 (en) | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | |
CN101432265B (zh) | 11-β-羟类固醇脱氢酶1的抑制剂 | |
US7265131B2 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
AU2008239179B2 (en) | Fused bicyclic heteroaryl derivatives | |
US20030212111A1 (en) | Heterocyclic modulators of nuclear receptors | |
KR20170072957A (ko) | 칼슘 방출-활성화 칼슘 통로의 조정제로서의 피라졸 유도체 | |
CA2332957A1 (en) | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents | |
KR20090007371A (ko) | 11-베타-히드록시스테로이드 데히드로게나제 1의 억제제로서의 피페리디닐 치환 피롤리디논 | |
CN101248048B (zh) | 吡唑基lxr调节剂 | |
EP1615636A1 (en) | Bicyclic compounds as nr2b receptor antagonists | |
AU2007298540A1 (en) | 3 -amino- pyridine derivatives for the treatment of metabolic disorders | |
WO2004006922A1 (en) | Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20141003 |